[1] |
Snekvik I, Nilsen T, Romundstad PR, et al. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT study, Norway[J]. Br J Dermatol, 2019,180(1):94⁃99. doi: 10.1111/bjd.16885.
|
[2] |
Shreberk⁃Hassidim R, Galili E, Hassidim A, et al. Epidemiology and comorbidities of psoriasis among Israeli adolescents: a large cross⁃sectional study[J]. Dermatology, 2019,235(6):488⁃494. doi: 10.1159/000501032.
|
[3] |
Aune D, Snekvik I, Schlesinger S, et al. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose⁃response meta⁃analysis of prospective studies[J]. Eur J Epidemiol, 2018,33(12):1163⁃1178. doi: 10.1007/s10654⁃018⁃0366⁃z.
|
[4] |
Kunz M, Simon JC, Saalbach A. Psoriasis: obesity and fatty acids[J]. Front Immunol, 2019,10:1807. doi: 10.3389/fimmu.2019. 01807.
|
[5] |
Tupikowska⁃Marzec M, Kolačkov K, Zdrojowy⁃Wełna A, et al. The influence of FTO polymorphism rs9939609 on obesity, some clinical features, and disturbance of carbohydrate metabolism in patients with psoriasis[J]. Biomed Res Int, 2019,2019:7304345. doi: 10.1155/2019/7304345.
|
[6] |
Loft ND, Skov L, Rasmussen MK, et al. Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis[J]. PLoS One, 2018,13(2):e0192010. doi: 10.1371/journal.pone.0192010.
|
[7] |
Yu GI, Ha E, Park SH, et al. Association of tumor necrosis factor⁃α (TNF⁃α) promoter polymorphisms with overweight/obesity in a Korean population[J]. Inflamm Res, 2011,60(12):1099⁃1105. doi: 10.1007/s00011⁃011⁃0372⁃z.
|
[8] |
Shiao S, Xiao H, Dong L, et al. Genome wide DNA differential methylation regions in colorectal cancer patients in relation to blood related family members, obese and non⁃obese controls ⁃ a preliminary report[J]. Oncotarget, 2018,9(39):25557⁃25571. doi: 10.18632/oncotarget.25374.
|
[9] |
Hodeib AA, Neinaa Y, Zakaria SS, et al. Glucose transporter⁃1 (GLUT⁃1) expression in psoriasis: correlation with disease severity[J]. Int J Dermatol, 2018,57(8):943⁃951. doi: 10.1111/ijd.14037.
|
[10] |
Ogawa E, Sato Y, Minagawa A, et al. Pathogenesis of psoriasis and development of treatment[J]. J Dermatol, 2018,45(3):264⁃272. doi: 10.1111/1346⁃8138.14139.
|
[11] |
Francisco V, Pino J, Campos⁃Cabaleiro V, et al. Obesity, Fat mass and immune system: role for leptin[J]. Front Physiol, 2018,9:640. doi: 10.3389/fphys.2018.00640.
|
[12] |
Zhang Y, Yuan H, Bu P, et al. Recombinant leptin attenuates abdominal aortic aneurysm formation in angiotensin II⁃infused apolipoprotein E⁃deficient mice[J]. Biochem Biophys Res Commun, 2018,503(3):1450⁃1456. doi: 10.1016/j.bbrc.2018.07. 062.
|
[13] |
Han JH, Lee JH, Han KD, et al. Increased risk of psoriasis in subjects with abdominal obesity: a nationwide population⁃based study[J]. J Dermatol, 2019,46(8):695⁃701. doi: 10.1111/1346⁃8138.14939.
|
[14] |
Bavoso NC, Pinto JM, Soares M, et al. Psoriasis in obesity: comparison of serum levels of leptin and adiponectin in obese subjects ⁃ cases and controls[J]. An Bras Dermatol, 2019,94(2):192⁃197. doi: 10.1590/abd1806⁃4841.20197716.
|
[15] |
Nicolas S, Chabry J, Guyon A, et al. Adiponectin: an endogenous molecule with anti⁃inflammatory and antidepressant properties?[J]. Med Sci (Paris), 2018,34(5):417⁃423. doi: 10.1051/medsci/ 20183405014.
|
[16] |
Buechler C, Feder S, Haberl EM, et al. Chemerin isoforms and activity in obesity[J]. Int J Mol Sci, 2019,20(5). doi: 10.3390/ijms20051128.
|
[17] |
王媛, 张鼎伟, 霍佳, 等. Chemerin/chemR23对银屑病患者外周血Th9/Treg细胞平衡的影响[J]. 中南大学学报(医学版), 2019,44(2):144⁃149. doi: 10.11817/j.issn.1672⁃7347.2019.02. 005.
|
[18] |
Kumari B, Yadav U. Adipokine visfatin′s role in pathogenesis of diabesity and related metabolic derangements[J]. Curr Mol Med, 2018,18(2):116⁃125. doi: 10.2174/15665240186661807 05114131.
|
[19] |
Chyl⁃Surdacka KM, Bartosińska J, Kowal M, et al. Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities[J]. Adv Clin Exp Med, 2020,29(1):79⁃84. doi: 10.17219/acem/111820.
|
[20] |
Kwanbunjan K, Panprathip P, Phosat C, et al. Association of retinol binding protein 4 and transthyretin with triglyceride levels and insulin resistance in rural thais with high type 2 diabetes risk[J]. BMC Endocr Disord, 2018,18(1):26. doi: 10.1186/s12902⁃018⁃0254⁃2.
|
[21] |
Wang HM, Wu C, Jiang YY, et al. Retinol and vitamin a metabolites accumulate through RBP4 and STRA6 changes in a psoriasis murine model[J]. Nutr Metab (Lond), 2020,17:5. doi: 10.1186/s12986⁃019⁃0423⁃y.
|
[22] |
Hu Y, Zhu Y, Lian N, et al. Metabolic syndrome and skin diseases[J]. Front Endocrinol (Lausanne), 2019,10:788. doi: 10.3389/fendo.2019.00788.
|
[23] |
Buerger C. Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target[J]. Front Immunol, 2018,9:2786. doi: 10.3389/fimmu.2018.02786.
|
[24] |
Huang X, Liu G, Guo J, et al. The PI3K/AKT pathway in obesity and type 2 diabetes[J]. Int J Biol Sci, 2018,14(11):1483⁃1496. doi: 10.7150/ijbs.27173.
|
[25] |
Cataldi C, Mari NL, Lozovoy M, et al. Proinflammatory and anti⁃inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors[J]. Inflamm Res, 2019,68(7):557⁃567. doi: 10.1007/s00011⁃019⁃01238⁃8.
|
[26] |
Karczewski J, Śledzińska E, Baturo A, et al. Obesity and inflammation[J]. Eur Cytokine Netw, 2018,29(3):83⁃94. doi: 10.1684/ecn.2018.0415.
|
[27] |
Singh S, Facciorusso A, Singh A G, et al. Obesity and response to anti⁃tumor necrosis factor⁃α agents in patients with select immune⁃mediated inflammatory diseases: a systematic review and meta⁃analysis[J]. PLoS ONE, 2018,13(5):e0195123. doi: 10.1371/ journal.pone.0195123.
|
[28] |
Alotaibi HA. Effects of weight loss on psoriasis: a review of clinical trials[J]. Cureus, 2018,10(10):e3491. doi: 10.7759/cureus.3491.
|
[29] |
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents[J]. J Am Acad Dermatol, 2019,80(1):27⁃40. doi: 10.1016/j.jaad.2018.06.057.
|
[30] |
Hong JR, Lee YW, Choe YB, et al. Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real⁃world practice[J]. Dermatol Ther, 2019,32(3):e12875. doi: 10.1111/dth.12875.
|
[31] |
Storan ER, Galligan J, Barnes L. Phototherapy⁃induced erythema in patients with psoriasis and obesity treated with narrowband UVB phototherapy[J]. Photodermatol Photoimmunol Photomed, 2014,30(6):335⁃337. doi: 10.1111/phpp.12121.
|
[32] |
Vujic I, Herman R, Sanlorenzo M, et al. Apremilast in psoriasis ⁃ a prospective real⁃world study[J]. J Eur Acad Dermatol Venereol, 2018,32(2):254⁃259. doi: 10.1111/jdv.14598.
|
[33] |
Dalamaga M, Papadavid E. Can we better strategize our choice of pharmacotherapy for patients with co⁃morbid psoriasis and obesity?[J]. Expert Opin Pharmacother, 2019,20(11):1303⁃1308. doi: 10.1080/14656566.2019.1603294.
|
[34] |
Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity[J]. Expert Opin Pharmacother, 2019,20(7):863⁃872. doi: 10.1080/14656566.2019.1583207.
|
[35] |
Yang J, Wang Z, Zhang X. GLP⁃1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK[J]. Exp Mol Pathol, 2019,107:124⁃128. doi: 10.1016/j.yexmp.2019.01. 014.
|
[36] |
Ba W, Xu Y, Yin G, et al. Metformin inhibits pro⁃inflammatory responses via targeting nuclear factor⁃κB in HaCaT cells[J]. Cell Biochem Funct, 2019,37(1):4⁃10. doi: 10.1002/cbf.3367.
|
[37] |
Ba W, Xu Y, Yin G, et al. Metformin inhibits pro⁃inflammatory responses via targeting nuclear factor⁃κB in HaCaT cells[J]. Cell Biochem Funct, 2019,37(1):4⁃10. doi: 10.1002/cbf.3367.
|
[38] |
Chang G, Wang J, Song J, et al. Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta⁃analysis of randomized controlled trials[J]. J Dermatolog Treat, 2019:1⁃7. doi: 10.1080/09546634.2019.1610552.
|